ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1043

Ocular Scleral Pathology and Immune-Mediated Inflammatory Diseases. Study of 170 Patients from a Single Universitary Center

Lara Sanchez-Bilbao1, Inigo Gonzalez-Mazon2, José Luis Martín-Varillas3, David Martinez-Lopez4, Carmen Alvarez-Reguera1, Alba Herrero Morant1, Rosalia Demetrio-Pablo1, Vanesa Calvo-Río1, Miguel Ángel González-Gay5 and Ricardo Blanco1, 1Hospital Universitario Marques de Valdecilla, Santander, Spain, 2Hospital Universitario Marques de Valdecilla, Bezana, Spain, 3Hospital Sierrallana, Torrelavega, Spain, 4Hospital Universitario Marques de Valdecilla, Santander (SPAIN), Spain, 5Hospital Universitario Marques de Valdecilla, Santander, Cantabria, Spain

Meeting: ACR Convergence 2020

Keywords: autoimmune diseases, Eye Disorders, Inflammation

  • Tweet
  • Email
  • Print
Session Information

Date: Sunday, November 8, 2020

Title: Miscellaneous Rheumatic & Inflammatory Diseases Poster II: Sarcoidosis, Interstitial Lung Disease, & Inflammatory Eye Disease

Session Type: Poster Session C

Session Time: 9:00AM-11:00AM

Background/Purpose: Ocular scleral pathology (OSP) includes episcleritis and scleritis. Episcleritis is generally a benign disease with a self-limited course, while scleritis is a more severe ocular condition. Both may be associated with immune-mediated inflammatory diseases (IMID).

In a wide series with OSP our aim was to assess the a) epidemiological and clinical features and b) relationship with IMID.

Methods: Study of all consecutive patients studied in a single Universitary Hospital during the last ten years with: a) episcleritis and b) scleritis diagnosed by clinical features and slit-lamp (Watson and Hayreh criteria).

Results: We studied 170 patients (101 women/ 69 men) / 340 affected eyes with OSP (episcleritis=132; scleritis=38); mean age at diagnosis 49.03±14.11 years.

OSP was unilateral in 138 (81.2%), recurrent in 70 (41.2%) and chronic in 21 (12.4%). Most of them were idiopathic (n=85, 50%) while associated IMID were 43.5% (TABLE 1).

Topical treatment was used in all patients. In addition to systemic corticosteroids, conventional immunosuppressive and biological drugs were required in 52 cases (30.6%) and 20 (11.8%), respectively (TABLE 2). The main indication for biological therapy was the presence of underlying IMID.

Conclusion: Scleral pathology is a relatively frequent entity and it is necessary to exclude an underlying systemic disease.


Disclosure: L. Sanchez-Bilbao, None; I. Gonzalez-Mazon, None; J. Martín-Varillas, None; D. Martinez-Lopez, Lilly, 2; C. Alvarez-Reguera, None; A. Herrero Morant, None; R. Demetrio-Pablo, None; V. Calvo-Río, None; M. González-Gay, None; R. Blanco, None.

To cite this abstract in AMA style:

Sanchez-Bilbao L, Gonzalez-Mazon I, Martín-Varillas J, Martinez-Lopez D, Alvarez-Reguera C, Herrero Morant A, Demetrio-Pablo R, Calvo-Río V, González-Gay M, Blanco R. Ocular Scleral Pathology and Immune-Mediated Inflammatory Diseases. Study of 170 Patients from a Single Universitary Center [abstract]. Arthritis Rheumatol. 2020; 72 (suppl 10). https://acrabstracts.org/abstract/ocular-scleral-pathology-and-immune-mediated-inflammatory-diseases-study-of-170-patients-from-a-single-universitary-center/. Accessed .
  • Tweet
  • Email
  • Print

« Back to ACR Convergence 2020

ACR Meeting Abstracts - https://acrabstracts.org/abstract/ocular-scleral-pathology-and-immune-mediated-inflammatory-diseases-study-of-170-patients-from-a-single-universitary-center/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology